InChI: | InChI=1/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21) |
Specification: |
The Nicaraven is an organic compound with the formula C15H16N4O2. The IUPAC name of this chemical is N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide. With the CAS registry number 79455-30-4, it is also named as 3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediyl)bis-. The product's classification codes are Antioxidants; Drug / Therapeutic Agent; Protective Agents; Reproductive Effect.
Physical properties about Nicaraven are: (1)ACD/LogP: 0.44; (2)ACD/LogD (pH 5.5): 0.43; (3)ACD/LogD (pH 7.4): 0.44; (4)ACD/BCF (pH 5.5): 1.25; (5)ACD/BCF (pH 7.4): 1.27; (6)ACD/KOC (pH 5.5): 40.68; (7)ACD/KOC (pH 7.4): 41.27; (8)#H bond acceptors: 6; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 5; (11)Polar Surface Area: 66.4 Å2; (12)Index of Refraction: 1.584; (13)Molar Refractivity: 78.47 cm3; (14)Molar Volume: 234.3 cm3; (15)Polarizability: 31.11×10-24cm3; (16)Surface Tension: 53.6 dyne/cm; (17)Density: 1.213 g/cm3; (18)Flash Point: 338.4 °C; (19)Enthalpy of Vaporization: 93.96 kJ/mol; (20)Boiling Point: 635.9 °C at 760 mmHg; (21)Vapour Pressure: 4.53E-16 mmHg at 25°C.
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(NC(C)CNC(=O)c1cccnc1)c2cccnc2
(2)InChI: InChI=1/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
(3)InChIKey: KTXBOOWDLPUROC-UHFFFAOYAG
(4)Std. InChI: InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
(5)Std. InChIKey: KTXBOOWDLPUROC-UHFFFAOYSA-N
The toxicity data is as follows:
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
dog |
LDLo |
intravenous |
1500mg/kg (1500mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 23(Suppl, |
mouse |
LD |
unreported |
> 1gm/kg (1000mg/kg) |
|
European Patent Application. Vol. #0029602, |
mouse |
LD50 |
intravenous |
590mg/kg (590mg/kg) |
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 23(Suppl, |
rat |
LD50 |
intravenous |
840mg/kg (840mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 23(Suppl, |
|